拉罗替尼在儿童及年轻成人TRK融合实体瘤中的真实世界经验:SACHA-France研究
该前瞻性观察研究纳入25例<25岁接受拉罗替尼治疗的NTRK融合阳性实体瘤患者,总缓解率70%(95%CI 47-87),中位至最佳缓解时间2个月,2年无事件生存率和总生存率分别为61.3%和74.9%,治疗相关不良事件发生率8%。
要点
- 拉罗替尼在儿童及年轻成人NTRK融合实体瘤中总缓解率达70%。
- 婴儿纤维肉瘤2年EFS有高于中枢神经系统肿瘤的趋势。
- 治疗相关不良事件发生率低(8%),耐受性良好。
核心结论
- 拉罗替尼在婴儿纤维肉瘤以外的NTRK融合阳性恶性肿瘤中显示出有意义的疗效和良好的耐受性。
研究设计与样本
- 前瞻性观察研究,纳入2019年4月至2025年9月在临床试验外接受拉罗替尼治疗的25例<25岁患者(中位年龄2.8岁)。
主要发现
- 总缓解率为70%(95%CI 47-87),中位至最佳缓解时间为2个月。
- 2年无事件生存率为61.3%(95%CI 38.3-77.7),2年总生存率为74.9%(95%CI 52.4-87.9)。
- 婴儿纤维肉瘤2年EFS为72.9%(95%CI 26.7-92.9),中枢神经系统肿瘤为33%(95%CI 10.5-80),呈更高趋势。
- 治疗相关不良事件发生率为8%;5例出现疾病进展,其中2例确认获得性激酶域耐药突变。
临床怎么用
- 真实世界数据支持对NTRK融合阳性肿瘤进行早期分子检测。
- 疗效因组织学类型而异,临床管理策略需考虑组织学依赖的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Larotrectinib is a selective tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of NTRK fusion-positive tumors. Although its efficacy has been demonstrated in clinical trials, particularly in infantile fibrosarcoma (IFS), real-world data in pediatric populations remain limited. METHODS: We conducted a prospective observational study within the SACHA- France study, including patients < 25 years treated with larotrectinib outside clinical trials between April 2019 and September 2025. Clinical characteristics, molecular data, treatment indications, responses, survival outcomes, toxicity, treatment discontinuation, and resistance were analyzed. RESULTS: Twenty-five patients were included (median age 2.8 years): IFS (n = 9), extra-CNS tumors (n = 10) and CNS tumors (n = 6). Twelve patients were treated at progression, nine to avoid mutilating surgery, two for multifocal/metastatic disease, and two as maintenance for high relapse risk; five received upfront larotrectinib. The overall response rate was 70% (95% CI: 47-87), with a median time to best response of 2 months. Two-year event-free and overall survival rates were 61.3% (95% CI: 38.3-77.7) and 74.9% (95% CI: 52.4-87.9) respectively. A trend toward higher 2-year EFS was observed in IFS versus CNS tumors (72.9% [95% CI: 26.7-92.9] vs 33% [95% CI: 10.5-80]). Treatment-related adverse events were reported in 8% of patients. Disease progression occurred in five patients, with acquired resistance mutations in the kinase domain confirmed in two. CONCLUSION: Larotrectinib shows meaningful efficacy and favorable tolerance across NTRK fusion-positive malignancies beyond IFS. These real-world data support early molecular testing, highlight histology-dependent outcomes, and inform clinical management strategies.
引用
- Khouri C, Tandonnet J, Saumet L, et al. Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience. Eur J Cancer. 2026. PMID: 42372634. doi:10.1016/j.ejca.2026.116904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。